title: [The study of peculiarities of immunotropic action of statins in chronic heart failure of various etiology].
abstract: OBJECTIVE
  To study features of statin therapy in patients with heart failure (HF) of different etiology on immune system.
  
  
  METHODS
  The basic markers of immune activation in 43 patients with chronic heart disease (CHD) and HF in New York Heart Association (NYHA) class I to IV were studied. Mine age was 48 +/- 8 years (from 33 to 64 years). 43 patients with dilated cardiomyopathy (DCM) and HF were also observed. Mine age was 43 +/- 10 years (from 22 to 61 years). Parameters of systolic and diastolic left ventricle (LV) function were measured. Also non invasive methods for evaluation of endothelial function were used. Concentrations of hsCRP, IgG, IgA, IgM were measured using commercially available kits. IL 6, IL 8, sIL 2R, IL 18, IL 10, IFN Y, endothelin levels were measured using enzyme linked immunosorbent assay method.
  
  
  RESULTS
  Statin therapy has immunomodulation effect in patients with heart failure any etiology. This effect depends on etiology of HF. In CHD patients the decreasing of IFN Y, IL 8, sIL 2R, hsCRP and increasing of IL 18, IL 6 levels were observed. In DCM patients the decreasing of IL 8, IL 18, sIL 2R and increasing of IL 10 were observed. There was significant clinical improving in patients with DCM and HF after statin therapy. But there were no changes of endothelial function in patients with CHD and DCM. There were no changes of LV function in patients with CHD. So statin therapy may reduce level of proinflammatory mediators but not fully control inflammation process in patients with HF of different etiology.
authors.forename: K A
authors.initials: KA
authors.lastname: Zykov
authors.forename: S N
authors.initials: SN
authors.lastname: Tatenkulova
authors.forename: V Iu
authors.initials: VIu
authors.lastname: Mareev
authors.forename: B P
authors.initials: BP
authors.lastname: Masenko
authors.forename: T V
authors.initials: TV
authors.lastname: Balakhonova
authors.forename: M I
authors.initials: MI
authors.lastname: Tripoten'
authors.forename: E I
authors.initials: EI
authors.lastname: Kaznacheeva
authors.forename: E A
authors.initials: EA
authors.lastname: Beliavskiĭ
authors.forename: G A
authors.initials: GA
authors.lastname: Tkachev
authors.forename: Iu N
authors.initials: IuN
authors.lastname: Belenkov
mesh_terms: D000328:Adult; D002311:Cardiomyopathy, Dilated / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D016207:Cytokines / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006333:Heart Failure / Q000188:drug therapy / Q000209:etiology / Q000276:immunology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007109:Immunity / Q000187:drug effects*; D007136:Immunoglobulins / Q000097:blood; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000502:physiology; D055815:Young Adult
chemical_list: D016207:Cytokines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007136:Immunoglobulins